N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 23.5 CNY -6.67% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Nanjing Vazyme Biotech Co Ltd?
Write Note

Nanjing Vazyme Biotech Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanjing Vazyme Biotech Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Gross Profit
ÂĄ771.1m
CAGR 3-Years
-18%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Gross Profit
ÂĄ3.3B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
22%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ11.7B
CAGR 3-Years
3%
CAGR 5-Years
26%
CAGR 10-Years
38%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Nanjing Vazyme Biotech Co Ltd
Glance View

Market Cap
9.3B CNY
Industry
Biotechnology

Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. The company is headquartered in Nanjing, Jiangsu and currently employs 1,409 full-time employees. The company went IPO on 2021-11-15. The firm's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The firm's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.

Intrinsic Value
23.45 CNY
Fairly Valued
Intrinsic Value
Price
N

See Also

What is Nanjing Vazyme Biotech Co Ltd's Gross Profit?
Gross Profit
771.1m CNY

Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Gross Profit amounts to 771.1m CNY.

What is Nanjing Vazyme Biotech Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
41%

Over the last year, the Gross Profit growth was -65%. The average annual Gross Profit growth rates for Nanjing Vazyme Biotech Co Ltd have been -18% over the past three years , 41% over the past five years .

Back to Top